| Name | Title | Contact Details |
|---|
Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma, Texas and several subsidiaries are part of the largest customer-owned health benefits company in the United States and fourth largest overall. We offer a full range of managed care programs for individuals, families, employer groups and Medicare beneficiaries. And we focus on improving the health and wellness of our members and communities by: • offering a variety of health insurance and wellness products to employers and individuals • keeping our focus local • participating in our communities in meaningful ways such as Blue Corps employee volunteer program and our Healthy Kids, Healthy Families initiative The commitment of our employees to providing superior services and products has made us one of the fastest growing health care insurance companies in the nation. Blue Cross and Blue Shield of Illinois Blue Cross and Blue Shield of Montana Blue Cross and BlueShield of New Mexico Blue Cross and Blue Shield of Oklahoma Blue Cross and Blue Shield of Texas Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. We are an Equal Opportunity Employment / Affirmative Action employer dedicated to workforce diversity and a drug-free and smoke-free workplace. Drug screening and background investigation are required, as allowed by law. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, national origin, disability, or protected veteran status.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Cytheris is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intertek Pharmaceutical Services is a Whitehouse, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WCG is the world`s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG`s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.